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Background: The purpose of this analysis is to report the change in quality of life (QoL) after
treatment with the Argus II Epiretinal Prosthesis in patients with end-stage retinitis
pigmentosa.
Methods: The Vision and Quality of Life Index (VisQoL) was used to assess changes in QoL
dimensions and overall utility score in a prospective 30-patient single-arm clinical study.
VisQoL is a multi-attribute instrument consisting of six dimensions (injury, life, roles,
assistance, activity and friendship) that may be affected by visual impairment. Within each
dimension, patients were divided into two groups based on how much their QoL was affected
by their blindness at baseline (moderate/severe orminimal). Outcomes were compared within
each dimension sub-group between baseline and the combined follow-up periods using the
Friedman test. In addition, data from the six dimensions were combined into a single utility
score, with baseline data compared to the combined follow-up periods.
Results: Overall, 80 per cent of the patients reported difficulty in one ormore dimensions pre-
implant. Composite VisQoL utility scores at follow-up showed no statistically significant change
from baseline; however, in three of the six VisQoL dimensions (injury, life and roles), patients
with baseline deficits showed significant and lasting improvement after implantation with
Argus II. In two of the three remaining dimensions (assistance and activity), data trended
toward an improvement. In the final VisQoL dimension (friendship), none of the patients
reported baseline deficits, suggesting that patients had largely adjusted to this attribute.
Conclusion: Patients whose vision negatively affected them with respect to three VisQoL
dimensions (that is, getting injured, coping with the demands of their life and fulfilling their
life roles) reported significant improvement in QoL after implantation of the Argus II retinal
prosthesis. Furthermore, the benefit did not deteriorate at any point during the 36-month
follow-up, suggesting a long-term, durable improvement.
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Retinitis pigmentosa (RP) is a hereditary dis-
ease that results in the progressive degenera-
tion of photoreceptor cells (rods and cones)
in the outermost layer of the retina. The
progressive loss of photoreceptor cells limits
the information that is available for
processing by secondary neurons, eventually
resulting in total blindness. Retinal prosthetic
devices are intended to replace the function
of dead or dying photoreceptor cells in
patients with late-stage RP by electrically stim-
ulating the remaining secondary neurons.1,2
There is no cure for RP. VitaminA therapy,
as well as treatment with docosahexaenoic
acid and/or antioxidants, has been shown
© 2016 Optometry Australia Clinical and Experimental Optometry 2016
1
C L I N I C A L  A N D  E X P E R I M E N T A L
2017; 100: 144–150
Clinical and Experimental Optometry 100.2 March 2017 © 2016 The Authors. Clinical and Experimental Optometry pub shed by John Wiley & Sons Australia, Ltd 
144 on behalf of Optometry Australia
 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permitsuse and distribution in any medium,
 provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
to slow the rate of retinal degeneration,
although there is no evidence that it
halts photoreceptor degeneration.3,4 Other
therapeutic modalities under development
include gene therapy, stem cell transplanta-
tion and pharmacologic options to preserve
the remaining photoreceptors. At present, a
retinal prosthetic device is the only therapy
commercially available to treat patients with
advanced RP.
The Argus II Retinal Prosthesis System
(Second Sight Medical Products, Inc,
Sylmar, California, USA) was approved by
the Food and Drug Administration (FDA)
in 2013 for treatment of late-stage RP. The
device includes a small video camera that is
built into a special pair of eyeglasses. The
camera is connected to a video processing
unit worn by the patient, which converts
the video input to electronic signals that
are transmitted wirelessly to an electrode ar-
ray (60 electrodes arranged in a six by ten
grid) implanted on the surface of the retina.
The array stimulates remaining ganglion
and/or bipolar cells in the retina and this
activation pattern is then transmitted by the
optic nerve to the brain, where it is
perceived as patterns of light. The patient
learns to interpret these patterns so he or
she can distinguish the movement and
outlines of objects.
The safety and benefit of Argus II were
established from a prospective 30-patient
single-arm clinical study.5,6 Patients partici-
pating in the study had baseline visual acuity
of worse than 2.9 logMAR in both eyes (worse
than 6/4,764 in Snellen notation), as mea-
sured with a grading visual acuity test and
the device was implanted in the worse-seeing
eye. Efficacy was established from three
computer-based, objective tests of basic visual
skills, intended to measure incremental
changes in a low-vision population. Func-
tional vision or the ability to complete every-
day tasks, was also measured with the device
turned both on and off.7
In addition to objective and observer-rated
outcome measures, the FDA advises using a
patient-reported outcome measure, such as
a quality of life (QoL) instrument, when the
concept being measured is best known by
the patient or best measured from the
patient’s perspective.9 QoL is an important
aspect of treatment efficacy; it is reported
that QoL is reduced in patients with RP com-
pared to normal controls.10 However, it has
also been reported that patients with RP
may adapt to progressive loss of vision,
resulting in a minimal decrease in self-
reported QoL, particularly within certain di-
mensions.11 To the authors’ knowledge,
there are no published reports on the
change in QoL in patients implanted with a
retinal prosthesis.
To evaluate the effect of some restoration
of vision on RP patients’ QoL, QoL was
measured in the Argus II clinical trial with a
vision-specific multi-attribute utility instru-
ment developed by researchers at The
University of Melbourne (East Melbourne,
Victoria, Australia) and Monash University
(Clayton, Victoria, Australia).8 The Vision
and Quality of Life Index (VisQoL) differs
from generic QoL instruments insofar as it
attempts to be more responsive to clinically
relevant changes in vision.
This analysis is the first published report
on VisQoL changes in patients with RP
implanted with the Argus II retinal prosthe-
sis. It also represents one of the first
attempts to measure changes in QoL in a
population with profound loss of vision
and who receive a sight restoration inter-
vention. Finally, this analysis identifies
which VisQoL dimensions are most influ-
enced by end-stage RP and which QoL
subscales are most affected by implantation
of a retinal prosthesis.
METHODS
Study design and patients
Thirty patients were enrolled in a single-arm,
prospective, unmasked clinical trial con-
ducted at 10 centres in the USA and
Europe. The study size was necessarily limited
to reflect the rarity of the disease, which
received a Humanitarian-Use Device desig-
nation, similar to orphan status for pharma-
ceuticals, from the FDA. Subjects served as
their own controls, with comparisons made
between baseline and post-implant follow-
up measurements or with the device turned
on and off. The trial was and continues to
be conducted in accordance with all relevant
national and international regulations for
medical device clinical trials, including the
Declaration of Helsinki. All patients com-
pleted a minimum of three years follow-up.
Additional information on the study design
is available at www.clinicaltrials.gov, trial
registration number NCT00407602.
Patients were eligible to enrol if they had
a confirmed history of RP (in the USA) or
outer retinal degeneration (in Europe), with
bare light perception or worse vision in both
eyes, functional ganglion cells and intact
optic nerves. Exclusion criteria included
various ophthalmic diseases or conditions
and untreated depression, among other
criteria.
Subject demographics are summarised
in Table 1. All patients had baseline
visual acuity worse than 2.9 logMAR in
both eyes.
VisQoL
Vision-specific QoL was measured using the
VisQoL multi-attribute utility instrument.
VisQoL covers six dimensions (or attributes)
of QoL as detailed in Table 2. Survey options
are registered on a five- or six-point scale. A
utility score for each dimension is estimated,
based on participant surveys using the time
trade-off method.12 All six dimensions are
combined using a multiplicative model
resulting in a utility score ranging from zero
to one (where zero represents death and
one represents full health). Although the
instrument has been validated for a
low-vision population, it has not been vali-
dated for patients with RP or patients with
severe loss of vision as found in the Argus
II cohort.
The VisQoL survey was administered to all
30 patients at baseline. One patient was
explanted at 14months and thus was with-
drawn from the study and from the analysis.
Follow-up visits were completed at three, six,
12, 18, 24 and 36months. Device outcomes
were considered stable beginning with the
12-month follow-up visit.
Age at time of implant
Mean 58.3
Median 57.9
Range 27.8–77.4
Female : male ratio 9:21
Race
White n = 27 (90%)
Other n = 3 (10%)
Years since first diagnosis of RP
Mean 15.9
Median 17.5
Range 1.5–26.9
RP: retinitis pigmentosa
Table 1. Demographic data from the Argus
II clinical trial
QoL in patients with retinal prosthesis Duncan et al.
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Statistical analysis
Computations were carried out using SAS 9.4
(SAS Inc., Cary, North Carolina, USA).
Data from the VisQoL questionnaire were
converted to a single utility score (ranging
between zero to one) using the scoring algo-
rithm provided by the Assessment of Quality
of Life group.13 The resulting baseline scores
were analysed with descriptive statistics and
analysis of variance (ANOVA) was used to
compare baseline data with that generated
at 12, 18, 24 and 36months.
A further analysis was done within each of
the six VisQoL dimensions. For this analysis,
patients who perceived little or no effect of
their loss of vision on QoL were considered
separately from those whose blindness was af-
fecting their QoL at baseline with scores
shown in bold in Table 2. Outcomes (mean
survey scores) were compared within each
sub-group between baseline and the com-
bined follow-up periods (12 to 36months)
using the Friedman test (that is, a longitudi-
nal analysis was completed using repeated
measurements and a non-parametric test
method).
In spite of limited demographic data,
univariate and multivariate tree analysis
with baseline utility scores were completed.
Pearson correlations with age and years
with RP are reported. The t-test was used
to analyse outcomes by gender. Multivari-
ate regression tree analysis was completed
on four groups defined by age, gender
and years with RP.
RESULTS
Overall baseline (pre-implant) utility scores
from analysis of all six VisQoL dimensions
are detailed in Figure 1.Within the 30-patient
cohort, baseline utility scores ranged
0.22–0.99 (normal distribution) even though
all patients had significant visual loss (worse
than 2.9 logMAR).
VisQoL utility scores at follow-up (post-
implant) showed no statistically significant
change from baseline. Mean utility scores
ranged between 0.63 to 0.67 throughout the
follow-up period (versus 0.62 at baseline).
Because of the large distribution of base-
line utility scores, patients within each of the
six VisQoL dimensions were sub-divided into
those who reported minimal difficulty in
performing any given dimension at baseline
in spite loss of vision and those who reported
having at least moderate difficulty (Table 2,
which identifies in bold text the responses
representing at least moderate difficulty).
Outcomes (change in survey scores) for
five of the six VisQoL dimensions within the
sub-group of patients whose blindness was af-
fecting their QoL at baseline are provided in
Table 3. One VisQoL dimension (friendship
– item 3 in Table 2) had no patients who re-
ported difficulty caused by their visual loss at
baseline and therefore, was not analysed.
Although the data are not normally
Dimension Survey scale
1. Does my vision make it likely I will injure myself
(that is, when moving around the house, yard,
neighbourhood or workplace)?
1 = Unlikely
2 = Small chance
3 = Good chance
4 = Very likely
5 = Almost certainly
2. Does my vision make it difficult to cope with the
demands in my life?
1 = No effect
2 = Not difficult
3 = Little difficulty
4 =Moderately difficult
5 = Very difficult
6 = Unable
3. Does my vision affect my ability to have
friendships?
1 = Easy
2 = No effect
3 =More difficult
4 = Lot more difficult
5 = Extremely difficult
6 = Unable
4. Do I have difficulty organising any assistance
I may need?
1 = Not difficult
2 = Little difficulty
3 =Moderately difficulty
4 = Lot of difficulty
5 = Unable
5. Does my vision make it difficult to fulfil the roles
I would like to fulfil in my life (for example, family
roles, work roles, community roles)?
1 = No effect
2 = Not difficult
3 = Little difficulty
4 =Moderately difficulty
5 = Very difficult
6 = Unable
6. Does my vision affect my confidence to join
in everyday activities?
1 =More confident
2 = No effect
3 = Little less confident
4 =Moderately less confident
5 = Lot less confident
6 = Not confident
Table 2. Vision and Quality of Life Index (VisQoL) dimensions with scoring scale. Within
each dimension, lower scores reflect little to no effect on quality of life caused by loss of
vision. Scores shown in bold represent worse outcomes associated with the visual loss. All
six dimensions are combined to form a single utility score ranging 0-1. Each dimension is
identified by the term underlined (for example, dimension 1 is referred to as ‘injury’
dimension).
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distributed within each dimension, mean
values are provided.
Within each VisQoL dimension, between
nine and 20 patients (30 to 67 per cent)
reported at least moderate impact of their
visual loss on their QoL. The remaining
patients self-reported minimal difficulty in
performing any given dimension at base-
line. Overall, 80 per cent of the cohort re-
ported a significant impact of their vision
on QoL at baseline in at least one of the
five affected dimensions, confirming that
the majority of patients had baseline QoL
deficits.
In three dimensions (injury, life and roles),
those whose QoL was affected by their loss of
vision had significant improvement in the
follow-up phase of the study (that is, survey
scores decreased in value). For these three di-
mensions, at least 50 per cent of the subjects
reported their vision negatively affected their
QoL with respect to the dimension. Further-
more, those whose QoL was not affected by
their loss of vision within the same three di-
mensions had no significant change from
baseline at follow-up.
In the other two dimensions (assistance
and activity), data trended toward an
improvement in QoL, although there was in-
sufficient power to demonstrate significance
(less than one-third of the study cohort
reported difficulty at baseline in either
dimension).
The improvements in VisQoL scores within
the sub-group of subjects who reported an
impact of blindness on their QoL for injury,
life and roles dimensions were consistent
throughout the follow-up period. For
example, for the injury domain, outcomes
at each follow-up visit (12, 18, 24 and
36months), as well as the overall follow-
up analysis (combining all follow-up visits)
were significantly improved from baseline.
This in turn suggests that the measured im-
provement was stable and most likely not
the result of placebo, which is known to dete-
riorate over time.
Although demographic data collected on
the overall study cohort were limited, both
univariate and multivariate regression were
attempted on baseline utility scores using
three potential predictors: age, gender and
years since the diagnosis of RP, as measured
at time of implant (‘years with RP’). Because
patients were screened for untreated depres-
sion at enrolment, due to the concern that
depressed patients may show less motivation
to learn how to use the device, this important
covariate was not applicable in this popula-
tion.14 Furthermore, the population had
Figure 1. Normal distribution of Vision and Quality of Life Index (VisQoL) utility scores at baseline. The box-whisker plot at the bottom
summarises the VisQoL distribution, where the ‘whisker’ endpoints are theminimum andmaximum, the lower and upper ends of the ‘box’
are the first and third quartiles, the mean is located in the middle of the diamond with the ends of the diamond indicating the mean± 1
standard deviation and the vertical line inside the box indicates the median.
VisQoL
dimension Number
% of overall
cohort
Baseline mean
survey score
Follow-up mean
survey score p-value
Injury (item 1) 15 50 3.8 2.8 0.0362*
Life (item 2) 20 67 4.4 3.7 0.0069*
Assistance
(item 4)
9 30 3.1 2.4 0.1745
Roles (item 5) 16 53 4.6 3.8 0.0012*
Activity (item 6) 10 33 4.1 3.8 0.1026
Table 3. Survey scores for patients whose blindness was affecting their quality of life at
baseline for relevant dimensions. Scores reflect the average survey score at baseline and the
combined average score from 12 to 36months follow-up visits. Therefore, a decrease in
survey score reflects an increase in quality of life. Statistical significance is defined as
p< 0.05 and is designated with an asterisk.
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virtually no identifiable co-morbidities, which
are typical in other vision-impaired popula-
tions and which can affect QoL (for example,
patients with diabetic retinopathy have a high
frequency of coronary heart disease, ne-
phropathy or cerebrovascular disease15). As
already noted, visual acuity (for example,
weighted logMAR) was also not a covariate
since all patients had uniformly poor baseline
vision in both eyes.
Results from the univariate associations
with baseline utility scores showed that none
of the three potential predictors were statisti-
cally significant (Table 4).
Multivariate regression tree analysis was
completed, forming four groups using
gender, age and years with RP (Table 5).
The overall R2 (coefficient of determination)
was 0.167. Only males under the age of 66
with less than 40 years with RP showed a
propensity toward lower baseline utility
scores, although the model was inconclusive.
DISCUSSION
Eighty per cent of patients with RP reported
moderate to severe difficulty in one or more
VisQoL dimensions pre-implant. In three of
the six VisQoL dimensions (injury, life and
roles), patients whose blindness was affecting
their QoL at baseline showed significant and
lasting improvement after implantation with
Argus II. In two of the three remaining
dimensions (assistance and activity), data
appeared to show an improvement, although
there was insufficient power to demonstrate
significance. In the final VisQoL dimension
(friendship), none of the patients reported
significant baseline deficits. Overall, the com-
posite utility score showed no significant
change.
VisQoL was selected as an instrument for
use in the Argus II clinical study because it is
vision-specific, easy to administer and gener-
ates utility values. As with other vision-specific
instruments, it was both constructed and
confirmed in study samples with relatively
few patients with significant visual impair-
ment (for example, only nine per cent of
‘vision-impaired’ patients in the construction
study had visual acuity worse than 6/60).16
Furthermore, there was no indication that
the instrument was sensitive to patients with
profound low vision or worse. Very recently,
a new vision-related QoL questionnaire was
developed that is intended for patients with
severe loss of vision, which was not available
when the study was initiated but which
may be a more appropriate instrument
for this population.17
Relatively little data have been published
on the use of VisQoL in a clinical setting.
The one notable exception is Fenwick and
colleagues,18 who assessed the impact of dia-
betic retinopathy and/or macular oedema
on VisQoL utility values. In a study cohort of
203 diabetic patients, visual impairment
ranged from none (less than 0.18 logMAR)
to ‘profound’ (which in their definition was
worse than 0.78 logMAR). The authors con-
cluded that the reduction in VisQoL utility
scores correlated with profound visual im-
pairment (worse than 0.78 logMAR) but not
with mild, moderate or severe visual impair-
ment or disease severity.
In light of the limited sensitivity of VisQoL,
it is not surprising that the composite utility
score in the Argus II cohort showed no signif-
icant improvement over time, even though
33 per cent of patients had significant
improvements in visual acuity after three
years;6 however, it was surprising that the
baseline utility scores ranged from 0.22 to
0.99, even though all patients had profound
low vision (worse than 2.9 logMAR) and were
otherwise largely homogeneous (for exam-
ple, no untreated clinical depression, mini-
mal co-morbidities). Unfortunately, both
univariate and multivariate regression were
unable to explain the differences, reflecting
limited covariates. The high variability
among baseline utility scores suggests that
patients with RP have varying success in
adjusting to profound blindness in different
QoL dimensions.
The disparity in baseline utility scores
prompted analysis of each VisQoL dimen-
sion, considering those patients who self-
reported difficulty presented by their loss of
vision separately from those who reported
no impact of their blindness on QoL.
Analysing each individual dimension of a
multi-attribute utility score has been
recognised as a potentially useful method to
identify important changes in patient experi-
ences, particularly as patients value each
dimension differently.19 Furthermore, sub-
dividing each cohort based on pre-treatment
QoL values has been adopted in other
medical disciplines to establish treatment
efficacy.20
The level of adjustment or adaptation
among patients before treatment is fre-
quently taken into account in studies of
populations suffering from chronic, dis-
abling diseases, such as cancer, irreversible
visual loss and rheumatoid arthritis.21–23
The concept is that patients who adapt
and therefore accept their disease, will re-
cover some level of normality even before
treatment, which equates to higher baseline
QoL scores.24 In contrast, patients who do
not adjust to their disease typically have
low QoL and frequently a higher incidence
of depression.
As adaptation improves over time, particu-
larly with active rehabilitation, QoL may
actually be better in end-stage patients, as
opposed to patients with a new diagnosis.
This in turn may explain why a certain
Variable p-value
Age 0.7962
Years with RP 0.6578
Gender 0.4375
RP: retinitis pigmentosa
Table 4. Univariate associations with
baseline utility scores
Group Gender Age Years with RP Number
Mean and SD
utility score
1 Male <65.9 <39.6 9 0.4873 ± 0.1086
2 Male <65.9 ≥39.6 6 0.6823 ± 0.2063
3 Male ≥65.9 – 6 0.6732 ± 0.2380
4 Female – – 9 0.6727 ± 0.2553
Total – – – 30 0.6191 ± 0.2146
SD: standard deviation
Table 5. Four groups formed from regression tree analysis using gender, age and years
with retinitis pigmentosa (RP). Males under age 66 with less than 40 years with RP (Group
1) have lower average utility scores than all other groups. Overall R2 = 0.167.
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subset of the Argus II cohort had relatively
high QoL values at baseline, even though
most patients had a long disease history
and the study design excluded patients
with significant untreated depression. Thus,
considering only the sub-cohort of patients
who report moderate to high impact of vi-
sual loss at baseline on their QoL is a use-
ful method for determining if a new
therapy is efficacious, since only patients
with initial low QoL scores can show signif-
icant improvement.
Results from analysis of the Argus II cohort
identified a significant and lasting improve-
ment for patients whose blindness affected
their QoL in three domains: injury, life and
roles. In the other two domains for which pa-
tients reported difficulty at baseline (assis-
tance and activity), the possible trend was in
favour of improvement after implant, al-
though limited power prevented the change
from being statistically significant. Patients
who reported little or no difficulty at baseline
did not show any change or degradation of
QoL in any domain.
The stability of QoL improvements within
specific domains in Argus II patients is clini-
cally relevant. This point was highlighted in
a recent publication by Siqueira and col-
leagues,23 wherein NEI-VFQ-25 was used to
measure QoL changes in a RP population
treated with intravitreal bone-marrow stem
cells. Measurements were made at baseline
and at three and 12months after treatment.
In a cohort of 20 patients, there was a statisti-
cally significant improvement in QoL at three
months; however, there was no change rela-
tive to baseline at 12months, suggesting that
the benefit was lost over time. It was con-
cluded that the transitory clinical benefit
of stem-cell therapy (for example, as ob-
served in electroretinograms) degrades after
three months, which corresponds to the
loss in QoL. Therefore, it is reasonable to
expect that if clinical benefit were lost over
time in those Argus II patients reporting
difficulty at baseline, dimension-specific
QoL would also deteriorate; however, pa-
tients that benefited from use of the Argus
II device on this measure maintained that
benefit throughout the full follow-up period
of 36months.
The specific relevance of each of the six di-
mensions measured by VisQoL is difficult to
estimate; however, improvement in the injury
dimension may have direct impact on the
overall health and safety of blind patients.
As noted by the developers of the VisQoL in-
strument, visual impairment is associated with
increased risk of falls and hip fractures,
among other events. To the degree that
Argus II patients feel at less risk of injury as
a result of visual impairment, patients will be
more self-reliant. This in turn may have con-
siderable utility for both patients and
providers.
Data from the injury dimension are also
consistent with data on functional vision.7
Specifically, it was found previously that
patients could complete mobility tasks in
uncontrolled environments significantly
better with the device on versus off. Al-
though baseline functional vision was not
measured pre-implant, data confirmed that
use of the implant allowed patients to ma-
noeuvre across streets and on sidewalks
while avoiding obstacles, which is relevant
to avoiding injury.
The corresponding improvement in the
life and roles VisQoL dimensions also sug-
gests that in patients having difficulty coping
with, for example, family and other life de-
mands, treatment with Argus II improves
emotional well-being. As with improvements
within the injury dimension, it is very signifi-
cant that the improvement is measured
throughout the 36-month follow up.
The lack of patients who report significant
impact of their loss of vision within the friend-
ship dimension suggests that patients with
advanced RP may have minimal difficulty in
developing and/or maintaining interper-
sonal relationships. This in turn suggests that
at least within this population, the friendship
dimension is not relevant to establishing util-
ity for any therapy, including the Argus II, as
patients have found other means to compen-
sate for vision loss.
Strengths of this study include reporting
QoL in patients with profound low vision or
worse andmeasuring QoL after implantation
of a novel retinal prosthesis for a full
36months. Limitations include the small
patient population, reflecting the rarity of
RP and limited patient information avail-
able at baseline for use as possible covari-
ates (including the level of previous
rehabilitation, training and support). In par-
ticular, understanding the extent of prior
rehabilitation would have been helpful in
explaining the disparity in baseline utility
and domain scores, although this would
not have affected the change in QoL scores
after treatment.
It is unlikely that any single outcome mea-
sure represents a full picture of the benefit
of the Argus II system for any particular pa-
tient. It is important to note that the VisQoL
was one of a battery of visual function and
functional vision outcome measures used in
this clinical trial, all of which together showed
an overall trend of benefit from the Argus II
system.5–7
CONCLUSION
The VisQoL was used to measure changes in
utility scores in a rare population implanted
with the Argus II retinal prosthesis system.
Utility scores for the overall patient cohort
were not significantly different between base-
line and follow-up periods; however, patients
whose vision negatively affected themwith re-
spect to three VisQoL dimensions (injury, life
and roles), reported significant and lasting
improvement in QoL after implantation of
the Argus II retinal prosthesis. No dimensions
showed a significant decline in QoL in any
sub-cohort. This outcome suggests that indi-
vidual QoL dimensions may be useful in
assessing QoL effects of treatment. These
data are consistent with other published out-
comes demonstrating that Argus II contrib-
utes to improvements in visual acuity and
functional vision and further demonstrates
that the Argus II treatment can produce sig-
nificant and lasting improvement in QoL re-
lated to the user’s perception of reduced
risk of injury, reduced difficulty of meeting
the demands of life and reduced difficulty
of fulfilling their roles in life.
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